Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ginkgo Bioworks
DNA
|
+$1.11B |
| 2 |
Peloton Interactive
PTON
|
+$877M |
| 3 |
Coupang
CPNG
|
+$455M |
| 4 |
DoorDash
DASH
|
+$423M |
| 5 |
Spotify
SPOT
|
+$387M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$2.87B |
| 2 |
Tesla
TSLA
|
+$1.41B |
| 3 |
Moderna
MRNA
|
+$1.35B |
| 4 |
Amazon
AMZN
|
+$928M |
| 5 |
NetEase
NTES
|
+$766M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 27.57% |
| 2 | Healthcare | 26.02% |
| 3 | Technology | 18.64% |
| 4 | Communication Services | 12.04% |
| 5 | Financials | 5.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NCNA
251
NuCana
NCNA
$6.12M
| $9.44M | ﹤0.01% |
732
| – | – |
|
252
Alector
ALEC
$199M
| $7.77M | ﹤0.01% |
340,352
+39,524
| +13% | +$1.11M |
|
253
Fortive
FTV
$18.6B
| $6.9M | ﹤0.01% |
129,799
-14,926
| -10% | -$817K |
|
254
British American Tobacco
BTI
$128B
| $6.85M | ﹤0.01% |
194,106
-23,111
| -11% | -$868K |
|
255
Relay Therapeutics
RLAY
$4.33B
| $6.72M | ﹤0.01% |
213,089
+20,568
| +11% | +$692K |
|
256
Lyell Immunopharma
LYEL
$360M
| $6.33M | ﹤0.01% |
21,374
+8,433
| +65% | +$2.53M |
|
257
TJX Companies
TJX
$178B
| $5.73M | ﹤0.01% |
86,893
-8,270
| -9% | -$577K |
|
258
Sixth Street Specialty
TSLX
$1.81B
| $5.07M | ﹤0.01% |
+228,078
| New | +$5.23M |
|
|
UXIN
259
Uxin Ltd
UXIN
$282M
| $4.9M | ﹤0.01% |
17,761
| – | – |
|
260
American Well
AMWL
$230M
| $4.58M | ﹤0.01% |
25,128
+2,270
| +10% | +$492K |
|
|
SOHU
261
Sohu.com
SOHU
$357M
| $4.17M | ﹤0.01% |
200,140
| – | – |
|
|
SAGE
262
DELISTED
Sage Therapeutics
SAGE
| $3.82M | ﹤0.01% |
86,298
+6,033
| +8% | +$277K |
|
|
KLDO
263
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
| $3.6M | ﹤0.01% |
659,227
+766
| +0.1% | +$4.75K |
|
264
Summit Therapeutics
SMMT
$11.1B
| $2.19M | ﹤0.01% |
436,512
| – | – |
|
|
BRW
265
Saba Capital Income & Opportunities Fund
BRW
$339M
| $1.97M | ﹤0.01% |
216,396
-203,244
| -48% | -$1.87M |
|
|
UBX
266
DELISTED
Unity Biotechnology
UBX
| $1.77M | ﹤0.01% |
58,911
-171,500
| -74% | -$6.05M |
|
267
Korea Electric Power
KEP
$16B
| $1.61M | ﹤0.01% |
163,646
| – | – |
|
268
Adicet Bio
ACET
$74.7M
| $1.42M | ﹤0.01% |
11,352
| – | – |
|
269
Fortis
FTS
$28.7B
| $1.35M | ﹤0.01% |
30,457
| – | – |
|
270
WEC Energy
WEC
$35.1B
| $1.34M | ﹤0.01% |
15,233
| – | – |
|
271
Newmont
NEM
$119B
| $1.09M | ﹤0.01% |
20,172
+5,241
| +35% | +$309K |
|
|
APRN
272
DELISTED
Blue Apron Holdings, Inc. Class A Common Stock
APRN
| $1.09M | ﹤0.01% |
12,376
| – | – |
|
273
Exelon
EXC
$47B
| $1.08M | ﹤0.01% |
31,220
| – | – |
|
274
Jackson Financial
JXN
$8.8B
| $986K | ﹤0.01% |
+37,907
| New | +$1.03M |
|
275
Beam Therapeutics
BEAM
$2.84B
| $931K | ﹤0.01% |
10,700
+10,213
| +2,097% | +$1.03M |
|
Similar funds
Baillie Gifford & Co's Q3 2021 Portfolio in Review
As of Q3 2021, Baillie Gifford & Co held 509 positions worth $191B, down 6.8% from $205B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Baillie Gifford & Co's Q3 2021 filing shows 38 new, 113 increased, 204 reduced and 17 closed positions. Its largest new stake was Ginkgo Bioworks: 2,275,070 shares worth $1.05B. The largest sale was Alibaba, an estimated $2.87B.
By sector, the portfolio is most concentrated in Consumer Discretionary at 28% of assets, down from 29% a quarter earlier, followed by Healthcare and Technology.
- Baillie Gifford & Co's largest Q3 2021 buy was Ginkgo Bioworks: 2,275,070 shares worth $1.05B.
- Baillie Gifford & Co added most to Peloton Interactive in Q3 2021, an estimated $877M increase.
- Baillie Gifford & Co's biggest Q3 2021 reduction was Alibaba, cutting an estimated $2.87B.
- Baillie Gifford & Co fully exited EOG Resources in Q3 2021, selling an estimated $329M.
- Baillie Gifford & Co's ten largest holdings make up 40% of its $191B portfolio in Q3 2021.
- Baillie Gifford & Co opened 38 new positions and closed 17 in Q3 2021.
- Baillie Gifford & Co's portfolio value fell 6.8% quarter-over-quarter to $191B.
Based on Baillie Gifford & Co's 13F filing for Q3 2021, filed 19 Oct 2021.